Stock data
Rein Therapeutics, Inc. (RNTX)
Rein Therapeutics, Inc. (RNTX) reported revenue of US$0.00M and net income of -US$49.87M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | US$0.00M | — | -US$50.63M | -US$49.87M | — |
| 2024 | US$0.00M | — | -US$65.11M | -US$62.88M | — |
| 2023 | US$0.00M | — | -US$16.28M | -US$15.73M | — |
| 2022 | US$0.00M | — | -US$27.65M | -US$27.33M | — |
| 2021 | US$0.00M | — | -US$26.61M | -US$26.16M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | US$0.00M | -US$6.38M | — |
| 2026-03-31 | US$0.00M | -US$5.84M | — |
| 2025-12-31 | US$0.00M | -US$31.97M | — |
| 2025-09-30 | US$0.00M | -US$5.58M | — |
| 2025-06-30 | US$0.00M | -US$6.82M | — |
| 2025-03-31 | US$0.00M | -US$5.50M | — |
| 2024-12-31 | US$0.00M | -US$40.98M | — |
| 2024-09-30 | US$0.00M | -US$5.85M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.